Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2011

01.08.2011 | Hepatobiliary Tumors

Hepatocellular Carcinoma Expressing Cholangiocyte Phenotype Is a Novel Subtype with Highly Aggressive Behavior

verfasst von: Xin-Yuan Lu, MD, Tao Xi, MD, Wan-Yee Lau, MD, PhD, Hui Dong, MD, PhD, Zhen Zhu, MD, Feng Shen, MD, PhD, Meng-Chao Wu, MD, Wen-Ming Cong, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The pathobiological features and surgical outcomes of patients with classical hepatocellular carcinoma (HCC)-expressing cholangiocyte markers that we named dual-phenotype HCC (DPHCC) remain unclear. The purpose of this study was to assess the association between the phenotype and surgicopathologic features of DPHCC.

Methods

A retrospective single-center study was performed on the surgicopathologic features of DPHCC from 1530 consecutive surgical specimens. Immunohistochemical staining was performed with antibodies to hepatocytes (Hep Par 1/pCEA) and cholangiocytes (cytokeratin 19 [CK19]/mucin core protein-1 [MUC-1]).

Results

DPHCC accounted for 10.1% (n = 155) of total HCCs. The serum alfa-fetoprotein and CA19-9 were elevated in 87.7% (n = 136) and 20.7% (n = 32) of patients, respectively; the former had close correlation with the immunostaining of CK19 (P < 0.01). The combination of immunostaining intensities of CK19 and MUC-1 was significantly associated with tumor size, microvascular invasion, and satellite nodule formation (P < 0.05–0.01). Compared to patients with pure HCC, those with DPHCC had significantly lower overall survival (30.4 ± 3.7 vs. 43.6 ± 3.9 months, P < 0.05) and recurrence-free survival (13.2 ± 2.0 vs. 23.4 ± 2.5 months, P < 0.01), respectively. Multivariate Cox regression analyses identified CK19-positive expression to be an independent prognostic factor for both overall survival and recurrence-free survival.

Conclusions

DPHCC is a novel surgicopathologic entity that has a highly aggressive behavior and worse postoperative prognosis than pure HCC. Because the morphological features between DPHCC and conventional HCC overlap, we recommend that CK19 be routinely used in the pathological diagnosis of HCC for screening DPHCC.
Literatur
1.
Zurück zum Zitat Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010. p. 205–27. Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010. p. 205–27.
2.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef
3.
Zurück zum Zitat Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120–5.PubMedCrossRef Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120–5.PubMedCrossRef
4.
Zurück zum Zitat Zhang F, Chen XP, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008;52:224–32.PubMedCrossRef Zhang F, Chen XP, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008;52:224–32.PubMedCrossRef
5.
Zurück zum Zitat Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–84.PubMedCrossRef Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–84.PubMedCrossRef
6.
Zurück zum Zitat Cong W, Tan L, Zhang S, et al. Immunohistochemical spectrum in the detection and differentiation of intrahepatic neoplasms. Chin J Oncol. 2002;24:553–6. Cong W, Tan L, Zhang S, et al. Immunohistochemical spectrum in the detection and differentiation of intrahepatic neoplasms. Chin J Oncol. 2002;24:553–6.
7.
Zurück zum Zitat Wu PC, Fang JW, Lau VK, et al. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996;149:1167–75.PubMed Wu PC, Fang JW, Lau VK, et al. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996;149:1167–75.PubMed
8.
Zurück zum Zitat Ding SJ, Li Y, Shao XX, et al. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics. 2004;4:982–94.PubMedCrossRef Ding SJ, Li Y, Shao XX, et al. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics. 2004;4:982–94.PubMedCrossRef
9.
Zurück zum Zitat Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003;94:851–7.PubMedCrossRef Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003;94:851–7.PubMedCrossRef
10.
Zurück zum Zitat Yamamoto T, Uenishi T, Ogawa M, et al. Immunohistologic attempt to find carcinogenesis from hepatic progenitor cell in hepatocellular carcinoma. Dig Surg. 2005;22:364–70.PubMedCrossRef Yamamoto T, Uenishi T, Ogawa M, et al. Immunohistologic attempt to find carcinogenesis from hepatic progenitor cell in hepatocellular carcinoma. Dig Surg. 2005;22:364–70.PubMedCrossRef
11.
Zurück zum Zitat Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14:3850–9.PubMedCrossRef Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14:3850–9.PubMedCrossRef
12.
Zurück zum Zitat Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol. 2004;40:298–304.PubMedCrossRef Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol. 2004;40:298–304.PubMedCrossRef
13.
Zurück zum Zitat Lee KH, Kim YB, Cho SB, et al. Hepatocellular carcinoma with characteristic mucin production: a case report. Cases J. 2009;2:6789.PubMedCrossRef Lee KH, Kim YB, Cho SB, et al. Hepatocellular carcinoma with characteristic mucin production: a case report. Cases J. 2009;2:6789.PubMedCrossRef
14.
Zurück zum Zitat Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006;49:138–51.PubMedCrossRef Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006;49:138–51.PubMedCrossRef
15.
Zurück zum Zitat Aishima S, Nishihara Y, Kuroda Y, et al. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol. 2007;31:783–91.PubMedCrossRef Aishima S, Nishihara Y, Kuroda Y, et al. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol. 2007;31:783–91.PubMedCrossRef
16.
Zurück zum Zitat Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol. 2010;23:1180–90.PubMedCrossRef Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol. 2010;23:1180–90.PubMedCrossRef
17.
Zurück zum Zitat Dong H, Cong WL, Zhu ZZ, et al. Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Chin J Oncol. 2008;30:702–5. Dong H, Cong WL, Zhu ZZ, et al. Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Chin J Oncol. 2008;30:702–5.
18.
Zurück zum Zitat Ichikawa T, Yamamoto T, Uenishi T, et al. Clinicopathological implications of immunohistochemically demonstrated mucin core protein expression in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2006;13:245–51.PubMedCrossRef Ichikawa T, Yamamoto T, Uenishi T, et al. Clinicopathological implications of immunohistochemically demonstrated mucin core protein expression in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2006;13:245–51.PubMedCrossRef
19.
Zurück zum Zitat Zhuang PY, Zhang JB, Zhu XD, et al. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer. 2008;112:2740–8.PubMedCrossRef Zhuang PY, Zhang JB, Zhu XD, et al. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer. 2008;112:2740–8.PubMedCrossRef
20.
Zurück zum Zitat Yu Y, Lang Q, Chen Z, et al. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer. 2009;115:5132–8.PubMedCrossRef Yu Y, Lang Q, Chen Z, et al. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer. 2009;115:5132–8.PubMedCrossRef
21.
Zurück zum Zitat Tan J, Hytiroglou P, Wieczorek R, et al. Immunohistochemical evidence for hepatic progenitor cells in liver diseases. Liver. 2002;22:365–73.PubMedCrossRef Tan J, Hytiroglou P, Wieczorek R, et al. Immunohistochemical evidence for hepatic progenitor cells in liver diseases. Liver. 2002;22:365–73.PubMedCrossRef
22.
Zurück zum Zitat Crosby HA, Kelly DA, Strain AJ. Human hepatic stem-like cells isolated using c-kit or CD34 can differentiate into biliary epithelium. Gastroenterology. 2001;120:534–44.PubMedCrossRef Crosby HA, Kelly DA, Strain AJ. Human hepatic stem-like cells isolated using c-kit or CD34 can differentiate into biliary epithelium. Gastroenterology. 2001;120:534–44.PubMedCrossRef
23.
Zurück zum Zitat Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006;25:3818–22.PubMedCrossRef Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006;25:3818–22.PubMedCrossRef
24.
Zurück zum Zitat Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544–56.PubMedCrossRef Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544–56.PubMedCrossRef
25.
Zurück zum Zitat Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009;49:318–29.PubMedCrossRef Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009;49:318–29.PubMedCrossRef
26.
Zurück zum Zitat Fiegel HC, Gluer S, Roth B, et al. Stem-like cells in human hepatoblastoma. J Histochem Cytochem. 2004;52:1495–501.PubMedCrossRef Fiegel HC, Gluer S, Roth B, et al. Stem-like cells in human hepatoblastoma. J Histochem Cytochem. 2004;52:1495–501.PubMedCrossRef
27.
Zurück zum Zitat Liu C, Wang J, Ou QJ. Possible stem cell origin of human cholangiocarcinoma. World J Gastroenterol. 2004;10:3374–6.PubMed Liu C, Wang J, Ou QJ. Possible stem cell origin of human cholangiocarcinoma. World J Gastroenterol. 2004;10:3374–6.PubMed
28.
Zurück zum Zitat Ward SC, Thung SN, Lim KH, et al. Hepatic progenitor cells in liver cancers from Asian children. Liver Int. 2010;30:102–11.PubMedCrossRef Ward SC, Thung SN, Lim KH, et al. Hepatic progenitor cells in liver cancers from Asian children. Liver Int. 2010;30:102–11.PubMedCrossRef
Metadaten
Titel
Hepatocellular Carcinoma Expressing Cholangiocyte Phenotype Is a Novel Subtype with Highly Aggressive Behavior
verfasst von
Xin-Yuan Lu, MD
Tao Xi, MD
Wan-Yee Lau, MD, PhD
Hui Dong, MD, PhD
Zhen Zhu, MD
Feng Shen, MD, PhD
Meng-Chao Wu, MD
Wen-Ming Cong, MD, PhD
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2011
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1585-7

Weitere Artikel der Ausgabe 8/2011

Annals of Surgical Oncology 8/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.